Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00448396
Recruitment Status : Completed
First Posted : March 16, 2007
Last Update Posted : November 19, 2009
Sponsor:
Information provided by:
Novartis

Brief Summary:
To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.

Condition or disease Intervention/treatment Phase
Advanced Malignancies Drug: Patupilone Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
Study Start Date : March 2007
Actual Primary Completion Date : February 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Arm Intervention/treatment
Experimental: Patupilone Drug: Patupilone



Primary Outcome Measures :
  1. To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.

Secondary Outcome Measures :
  1. To evaluate the effects of patupilone on the pharmacodynamics of warfarin in patients with advanced malignancies.
  2. Safety and tolerability of patupilone when administered concomitantly with warfarin in patients with advanced malignancies will be assessed by AE's, SAE's and safety labs.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  • Age ≥ 18 years of age
  • Life expectancy ≥3 months
  • Histologically documented advanced solid tumors which have progressed after standard systemic therapy or for which standard systemic therapy does not exist
  • Agents containing warfarin or heparin must be discontinued 7 days prior to enrollment in the study

Exclusion criteria

  • History of/or active bleeding disorders
  • Known hypersensitivity to warfarin or related compounds
  • The use of vitamin K
  • Central lines that require anticoagulant maintenance
  • The use of agents containing warfarin and heparin
  • Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00448396


Locations
Layout table for location information
United States, Texas
San Antonio, Texas, United States
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Chair: Novartis Pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: External Affairs, Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00448396    
Other Study ID Numbers: CEPO906A2120
First Posted: March 16, 2007    Key Record Dates
Last Update Posted: November 19, 2009
Last Verified: November 2009
Keywords provided by Novartis:
Cancer
EPO
Patupilone
Solid tumors
Advanced malignancies
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Epothilone B
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action